- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05729360
Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus
February 6, 2023 updated by: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
"An Open Safety Study and Description of the Parameters of the Therapeutic Efficacy of the Drug for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus, With a Single Application in Patients With Confirmed COVID-19 Diagnosis"
Open prospective non-comparative study of safety and tolerability of the drug (GamCoviMab) with the description of the parameters of the therapeutic efficacy in patients with confirmed COVID-19 diagnosis.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Each potential patient for inclusion in the study must meet all of the following criteria:
- Presence of a written Informed Consent to participate in the study;
- Men and women aged 18 to 75 years inclusive;
- Positive SARS-CoV-2 test result ≤5 days prior to enrollment or clinical manifestations later confirmed by PCR;
- Oxygen saturation ≥93% without oxygen donation by any means, diagnosed with COVID-19 disease with symptom onset within 5 days of inclusion;
- Presence of several symptoms of mild or moderate severity at the time of inclusion in the study;
- At the time of screening for the study, the patient is not hospitalized;
Presence of high risk factors for severe COVID-19 and/or hospitalization and/or death, in the opinion of the investigator, not limited to the following:
- not fully vaccinated and unvaccinated patients
- elderly patients (over 60), including those with additional risk factors
- obesity
- immunocompromised patients, including those receiving immunosuppressive drugs for any indication
- with comorbidities (diabetes, diseases of the cardiovascular system, coagulopathy, chronic kidney disease, including conditions requiring dialysis, chronic lung disease, liver disease, etc.)
- Consent to use effective methods of contraception during the entire period of participation in the study.
- Able to carry out study visits.
Exclusion Criteria:
The patient will not be included in the study in the following cases:
- Inability to read Russian; inability or unwillingness to understand the essence of the study. Any other condition that limits the eligibility of obtaining informed consent or may affect the volunteer's ability to participate in the study;
- Pregnancy or breast-feeding;
Severe and extremely severe course of COVID-19:
- Oxygen saturation at rest according to pulse oximetry (SpO2) ≤ 93% OR
- PaO2/FiO2 ≤ 300 mm Hg OR
- Respiratory failure and need for invasive mechanical ventilation (with tracheal intubation) or ECMO OR
- Septic shock OR
- Multiple organ failure
- Prior therapy with plasma from a recovered COVID-19 patient or other anti-SARS CoV-2 mAbs for the treatment of current COVID-19 disease at study entry;
- The patient is currently hospitalized or, in the opinion of the investigator, may require hospitalization within the next 24 hours;
- Requires oxygen therapy due to COVID-19 disease or requires an increase in basal oxygen flow due to COVID-19 disease in individuals on chronic oxygen therapy due to non-COVID-19 related comorbidities;
- Confirmed active tuberculosis, AIDS;
- The presence of any life-threatening decompensated comorbidity which, in the opinion of the Investigator, makes the patient unsuitable for inclusion in the study;
- Body weight less than 40 kg;
- Volunteer participation in any other clinical trial within the last 90 days;
- Requires mechanical ventilation or the inevitable need for mechanical ventilation in the next 24 hours based on the current state of the patient;
- Suspected or proven serious active bacterial, fungal, viral, or other infection (other than COVID-19) that, in the opinion of the investigator, may pose a risk to the volunteer and affect the assessment of study endpoints;
- There are concomitant diseases requiring surgical intervention within the next month;
- Aggravated allergic history (including, but not limited to, erythema multiforme major, toxic epidermal necrolysis, Quincke's edema, polymorphic exudative eczema, a history of serum sickness, hypersensitivity or allergic reactions to the administration of immunobiological drugs, known allergic reactions to drug components, etc.);
- Severe infusion reactions in history;
- Alcohol or drug addiction.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with a verified diagnosis of COVID-19
|
A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events (AE)
Time Frame: within 28 days after administration of the drug
|
Occurrence of adverse events (AE) within 28 days after administration of the drug
|
within 28 days after administration of the drug
|
Occurrence of serious adverse events (SAEs)
Time Frame: within 180 days after administration of the drug
|
Occurrence of serious adverse events (SAEs) throughout the study
|
within 180 days after administration of the drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2023
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
February 6, 2023
First Submitted That Met QC Criteria
February 6, 2023
First Posted (Actual)
February 15, 2023
Study Record Updates
Last Update Posted (Actual)
February 15, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-GamCoviMab-2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China